Karyopharm Therapeutics Inc (NAS:KPTI)
$ 1.055 -0.015 (-1.4%) Market Cap: 122.87 Mil Enterprise Value: 109.03 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 72/100

Karyopharm Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 04:30PM GMT
Release Date Price: $1.22 (+4.27%)
Unidentified Analyst

Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve [Berce], I'm an equity research associate here at H.C. Wainwright, and it is my pleasure to welcome Richard Paulson, President and Chief Executive Officer of Karyopharm Therapeutics; and Reshma Rangwala, Chief Medical Officer.

So I'll turn it over to Richard Paulson.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Thanks, Steven. Thanks, H.C. Wainright for having us here today. We're pleased to be joining you and showing some more about the Karyopharm story. Just a little housekeeping before we begin. As you know, various comments we make today will be forward-looking statements, so please refer to our most recent 10-Q.

So Karyopharm is an innovation and patient-focused company, which is passionately driven in the submission to positively impact patient's lives and defeat cancer. And we're an organization and that is a leader in the science of the selective inhibition nuclear

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot